Ed Arce

Ed Arce is a managing director in equity research and a senior analyst covering companies in the biopharmaceuticals and specialty pharmaceuticals sectors for H.C. Wainwright & Co. Previously, Arce was a senior research analyst with ROTH Capital Partners. Prior to ROTH, he covered biotechnology, biopharmaceutical, specialty pharmaceutical and select medical device companies as an analyst at MLV & Co. Prior to MLV, Arce covered the biotechnology sector at Wedbush Securities, and large-cap pharmaceuticals at UBS Securities. Arce started his equity research career in 2005 as a research associate at First Albany Capital, covering specialty and generic pharmaceutical companies.
He holds a master of science degree in finance (MSF) degree from Boston College, as well as a master's degree in business administration and a bachelor's degree in civil engineering, both from Florida International University. Mr. Arce is a board-licensed professional engineer, and a Level III CFA candidate.
Recent Quotes
"DRRX's Phase 2b DUR-928 AH trial is set to begin in mid-2020."
—
Ed Arce, H.C. Wainwright & Co.
(3/4/20)
more >
"From a stock perspective, 2019 was a clear breakout year for DRRX."
—
Ed Arce, H.C. Wainwright & Co.
(1/3/20)
more >
"DRRX has a valuable greenfield opportunity here with DUR-928."
—
Ed Arce, H.C. Wainwright & Co.
(11/25/19)
more >
"An AdCom meeting for DRRX's POSIMIR is scheduled for Jan. 16, 2020."
—
Ed Arce, H.C. Wainwright & Co.
(11/20/19)
more >
"DRRX's psoriasis trial is on target for topline data by year-end 2019."
—
Ed Arce, H.C. Wainwright & Co.
(11/3/19)
more >
"DRRX's DUR-928 treatment led to improved prognosis in AH patients."
—
Ed Arce, H.C. Wainwright & Co.
(9/18/19)
more >
"DRRX earned a $10M milestone payment from Gilead."
—
Ed Arce, H.C. Wainwright & Co.
(9/10/19)
more >
"We expect substantial news flow from DRRX over the next five months."
—
Ed Arce, H.C. Wainwright & Co.
(8/2/19)
more >